Mira Keyes

List of Publications by Year
in descending order

Version: 2024-02-01

39 papers	1,760 citations	331670 21 h-index	302126 39 g-index
39 all docs	39 docs citations	39 times ranked	1552 citing authors

#	Article	IF	Citations
1	After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a population-based analysis. Brachytherapy, 2022, , .	0.5	1
2	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy, 2021, 20, 1114-1129.	0.5	26
3	Prostate brachytherapy intraoperative dosimetry using a combination of radiographic seed localization with a C-arm and deformed ultrasound prostate contours. Brachytherapy, 2020, 19, 589-598.	0.5	2
4	Clinical and pathological characteristics of bladder cancer in post brachytherapy patients. Pathology Research and Practice, 2020, 216, 152822.	2.3	5
5	High-dose-rate brachytherapy for localized penile cancer: Evolution of aÂtechnique. Brachytherapy, 2020, 19, 201-209.	0.5	11
6	Multi-scale tissue architecture analysis of favorable-risk prostate cancer: Correlation with biochemical recurrence. Investigative and Clinical Urology, 2020, 61, 482.	2.0	2
7	Large-scale DNA organization is a prognostic marker of breast cancer survival. Medical Oncology, 2018, 35, 9.	2.5	2
8	The American Brachytherapy Society and the American Radium Society Appropriate Use Criteria Genitourinary Committee Endorse the American Society of Clinical Oncology/Cancer Care Ontario Guidelines. Journal of Clinical Oncology, 2018, 36, 3342-3344.	1.6	2
9	Using a surgical prostate-specific antigen threshold of >0.2Âng/mL to define biochemical failure for intermediate- and high-risk prostate cancer patients treated with definitive radiation therapy in the ASCENDE-RT randomized control trial. Brachytherapy, 2018, 17, 837-844.	0.5	29
10	ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 286-295.	0.8	250
11	Quantification of large scale DNA organization for predicting prostate cancer recurrence. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2017, 91, 1164-1174.	1.5	10
12	Rectal Ulcers and Rectoprostatic Fistulas after ¹²⁵ I Low Dose Rate Prostate Brachytherapy. Journal of Urology, 2016, 195, 1811-1816.	0.4	17
13	Automated Region-based Prostate Cancer Cell Nuclei Localization. Part of a Prognostic Modality Tool for Prostate Cancer Patients. Analytical and Quantitative Cytopathology and Histopathology, 2016, 38, 59-69.	0.2	2
14	Current state of brachytherapy teaching in Canada: A national survey ofÂradiation oncologists, residents, and fellows. Brachytherapy, 2015, 14, 197-201.	0.5	27
15	Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapy. Brachytherapy, 2015, 14, 350-358.	0.5	5
16	Effect of aging and long-term erectile function after iodine-125 prostate brachytherapy. Brachytherapy, 2015, 14, 334-341.	0.5	18
17	Salvage low-dose-rate permanent seed brachytherapy for locally recurrent prostate cancer: Association between dose and late toxicity. Brachytherapy, 2015, 14, 342-349.	0.5	25
18	Patterns of Recurrence After Low-Dose-Rate Prostate Brachytherapy: A Population-Based Study of 2223 Consecutive Low- and Intermediate-Risk Patients. International Journal of Radiation Oncology Biology Physics, 2015, 91, 745-751.	0.8	18

#	Article	IF	Citations
19	Prostate-Specific Antigen at 4 to 5 Years After Low-Dose-Rate Prostate Brachytherapy Is a Strong Predictor of Disease-Free Survival. International Journal of Radiation Oncology Biology Physics, 2014, 88, 87-93.	0.8	54
20	Decline in acute urinary toxicity: A long-term study in 2011 patients with prostate brachytherapy within a provincial institution. Brachytherapy, 2014, 13, 46-52.	0.5	21
21	Late Urinary Side Effects 10ÂYears After Low-Dose-Rate Prostate Brachytherapy: Population-Based Results From a Multiphysician Practice Treating With a Standardized Protocol and Uniform Dosimetric Goals. International Journal of Radiation Oncology Biology Physics, 2014, 90, 570-578.	0.8	52
22	Incidence of Second Malignancies in Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy and Radical Prostatectomy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 934-941.	0.8	31
23	Establishing High-Quality Prostate Brachytherapy Using a Phantom Simulator Training Program. International Journal of Radiation Oncology Biology Physics, 2014, 90, 579-586.	0.8	43
24	Pride or prejudice: Does Phoenix flatter radiation therapy?. Brachytherapy, 2014, 13, 299-303.	0.5	6
25	Surgical Management of Node-positive Prostate Cancer: Perspectives from Breast Oncology. European Urology, 2014, 66, 202-203.	1.9	3
26	Whole prostate D90 and V100: A doseâ€“response analysis of 2000 consecutive 125I monotherapy patients. Brachytherapy, 2014, 13, 32-41.	0.5	32
27	DNA Ploidy Measured on Archived Pretreatment Biopsy Material May Correlate With Prostate-Specific Antigen Recurrence After Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 829-834.	0.8	8
28	Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program. Brachytherapy, 2013, 12, 343-355.	0.5	26
29	The dosimetric impact of supplementing pre-planned prostate implants with discretionary ¹²⁵I seeds. Journal of Radiotherapy in Practice, 2013, 12, 226-236.	0.5	1
30	Populationâ€based 10â€year oncologic outcomes after lowâ€doseâ€rate brachytherapy for lowâ€risk and intermediateâ€risk prostate cancer. Cancer, 2013, 119, 1537-1546.	4.1	99
31	Rectal toxicity and rectal dosimetry in low-dose-rate 125I permanent prostate implants: A long-term study in 1006 patients. Brachytherapy, 2012, 11, 199-208.	0.5	66
32	Outcomes following iodine-125 brachytherapy in patients with Gleason 7, intermediate risk prostate cancer: A population-based cohort study. Radiotherapy and Oncology, 2012, 103, 228-232.	0.6	24
33	Comparative analysis of prostateâ€specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU International, 2012, 109, 22-29.	2.5	391
34	Predictive Factors for Acute and Late Urinary Toxicity After Permanent Prostate Brachytherapy: Long-Term Outcome in 712 Consecutive Patients. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1023-1032.	0.8	163
35	Urinary Symptom Flare in 712 125I Prostate Brachytherapy Patients: Long-Term Follow-Up. International Journal of Radiation Oncology Biology Physics, 2009, 75, 649-655.	0.8	49
36	Segmental Urethral Dosimetry and Urinary Toxicity in Patients With No Urinary Symptoms Before Permanent Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2008, 72, 447-455.	0.8	44

#	Article	IF	Citations
37	Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?. International Journal of Radiation Oncology Biology Physics, 2006, 64, 825-834.	0.8	96
38	Predictive factors for erectile dysfunction in men with prostate cancer after brachytherapy: Is dose to the penile bulb important?. International Journal of Radiation Oncology Biology Physics, 2005, 63, 155-163.	0.8	68
39	125I reimplantation in patients with poor initial dosimetry after prostate brachytherapy. International Journal of Radiation Oncology Biology Physics, 2004, 60, 40-50.	0.8	31